CTRI/2019/07/020236尚未招募未知
Fractionated cyclophosphamide with chemo-immunotherapy in patients with newly diagnosed DLBCL- A Randomised Open label study - SCUBA
Dr Gaurav Prakash0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Newly diagnosed DLBCL with any of the following characteristics
- •a. ABC phenotype on IHC according to Hans Protocol
- •b. IPI ranging from 2-5
- •c. Bulky baseline disease with at least one node/mass measuring >7.5cm
- •d. More than one extra nodal site involvement
- •e. Stage III/IV
- •2. Able to understand and provide an informed consent
- •3. ECOG performance status must be less than or equal to 2 at the time of randomisation
排除标准
- •1. Active infection with hepatitis b/hepatitis c/HIV
- •2. Documented CNS disease
- •3. History of another lymphoma in the past which might have transformed to DLBCL
- •4. History of hematuria in the last 6 months
研究者
相似试验
进行中（未招募）
2 期
Short treatment with the drug cyclophosphamide in bowel cancerStage II-IVA diagnosed colorectal cancerBowel cancerCancerISRCTN12508004Cardiff University500
已完成
不适用
Standard chemotherapy combination (Cyclophosphamide, Hydroxydaunorubicin, Vincristine, Prednisolone [CHOP]) with 1, 3 or 6 cycles of the monoclonal anti-CD20-antibody. Rituximab in first line therapy of follicular non-Hodgkin?s lymphoma.Follicular Lymphoma World Health Organisation (WHO) Grade I and II, Stage 3-4LymphomaCancerISRCTN47525145niversity of Heidelberg (Germany)120
进行中（未招募）
不适用
Immunoablation with Cyclophosphamide at high dosage and Rabbit antithymoglobulin followed by autologous hematopoietic stem cell transplantation in severe multiple sclerosis - LIGHTVERIFICARE Patients with multiple sclerosis, age between 18 and 50MedDRA version: 6.1Level: PTClassification code 10028245EUCTR2006-002562-19-ITDipartimento di Neuroscienze Oftalmologia e Genetica DINOG - Universita di Genova12
进行中（未招募）
1 期
Cyclophosphamide as graft-versus-host prophylaxis after allogeneic stem celltransplantation for multiple myeloma. A phase II study.Multiple myelomaEUCTR2016-002557-38-DEniversity Medical Center Hamburg-Eppendorf50
进行中（未招募）
1 期
Graft-versus-host response after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantatioWomen and men with a hematologic malignancy for which a reduced-intensity conditioning allo-SCT is indicatedMedDRA version: 19.0Level: PTClassification code 10053239Term: Prophylaxis against graft versus host diseaseSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2016-002129-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)88